

---

## WilmerHale Advises Arteaus Therapeutics in Sale of Emgality Royalty to Royalty Pharma for \$260M

APRIL 2, 2019

On April 1, 2019, Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded by Atlas Venture and OrbiMed, [announced](#) that Arteaus has sold its royalty interest on future global net sales of Eli Lilly and Company's (NYSE: LLY) Emgality (galcanezumab), an anti-CGRP antibody for the prevention of migraine, to Royalty Pharma for \$260 million.

WilmerHale represented Arteaus in the deal, with a team led by [Steve Singer](#) and [Joe Conahan](#) that included [Julie Hogan Rodgers](#), [John Sigel](#), [Brandt Tierney](#) and [Tyler Rostock](#).